BIORESEARCH MONITORING TECHNICAL CONFORMANCE GUIDE

Technical Specifications Document

This Document is Referenced by the Following Draft Guidance Document:

Standardized Format for Electronic Submission of NDA and BLA Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for CDER Submissions

For questions regarding this technical specifications document, contact <u>CDER-BIMO-NDA-BLA-request@fda.hhs.gov</u>.

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER)



BIORESEARCH MONITORING TECHNICAL CONFORMANCE GUIDE

July 27, 2020

Date	Version	Summary of Changes
12/28/2017	1.0	Original Version
07/23/2020	2.0	1. Corrected footnote hyperlinks
		2. Edited variable names in
		examples and tables to
		maintain consistency across
		document
		3. Clarified document, listings,
		and data requests
		4. Deleted request for SITEFFE
		and SITEFFS variables in
		clinsite.xpt
		5. Added COHORT variable
		6. Revised PROTVIOL variable
		to IMPDEV and NOIMPDEV
		variables
		7. Provided additional
		instructions for placement of
		files per eCTD format

Revision History

TABLE OF CONTENTS

I.	CLINICAL STUDY-LEVEL INFORMATION	1
А. В.	COMPREHENSIVE AND READILY LOCATED LIST OF ALL CLINICAL SITES TABLE LISTING ALL ENTITIES TO WHOM SPONSOR HAS CONTRACTED CLINICAL STUDY-RELATED ACTIVITIES	
C.	PROTOCOL, PROTOCOL AMENDMENTS, AND ANNOTATED CASE REPORT FORM	
II.	SUBJECT-LEVEL DATA LINE LISTINGS BY CLINICAL SITE	2
А. В.	ORGANIZATION OF THE SUBJECT-LEVEL DATA LINE LISTINGS SITE-SPECIFIC LISTINGS FORMAT	
III.	SUMMARY-LEVEL CLINICAL SITE DATASET	5
A. B. C.	ORGANIZATION OF THE SITE-LEVEL DATASET VARIABLES AND VARIABLE NAMES FOR SITE-SPECIFIC EFFICACY RESULTS CREATING THE DATA FILE (TEMPLATE AND STRUCTURE)	5
IV.	SUBMITTING BIMO CLINICAL DATA IN THE ECTD FORMAT	7
A. B. C. D. E. F.	STUDY TAGGING FILE ECTD FOLDER STRUCTURE FOR CLINICAL STUDY-LEVEL INFORMATION AND SUBJECT-LEVEL LINE LIS BY CLINICAL SITE ECTD FOLDER STRUCTURE FOR SUMMARY-LEVEL CLINICAL SITE DATASET FILE FORMAT LEAF TITLES SUBMISSION	STINGS 7 8 8 9
APPE	NDIX 1: CLINICAL STUDY-LEVEL INFORMATION	10
APPE	NDIX 2: FORMATTING SUBJECT-LEVEL DATA LINE LISTINGS BY CLINICAL SITE	11
APPE	NDIX 3: CLINICAL SITE DATA ELEMENTS SUMMARY LISTING	14
APPE	NDIX 4: EXAMPLES	17

Bioresearch Monitoring Technical Conformance Guide

This technical conformance guide, when finalized, will represent the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the FDA staff responsible for this technical conformance guide. If you cannot identify the appropriate FDA staff, send an email to <u>cder-edata@fda.hhs.gov</u> or <u>cber.cdisc@fda.hhs.gov</u>.

10

1

11 This Bioresearch Monitoring Technical Conformance Guide (Guide) provides current FDA

12 specifications, recommendations, and general considerations for preparing and submitting

13 Clinical Study-Level Information, Subject-Level Data Line Listings by Clinical Site, and a

14 Summary-Level Clinical Site Dataset that are used by the Center for Drug Evaluation and

15 Research (CDER) for planning of Bioresearch Monitoring (BIMO) inspections in electronic

16 format for new drug applications (NDAs), biologics license applications (BLAs), and NDA or 17 BLA supplemental applications containing clinical data that are regulated by CDER¹. It also

BLA supplemental applications containing clinical data that are regulated by CDER.¹ It also applies when these data and information are submitted under certain investigational new drug

applications² (INDs) in advance of a planned NDA, BLA, or supplemental submission.

20 21

22

23 24

25

30

31

I. CLINICAL STUDY-LEVEL INFORMATION

A. Comprehensive and Readily Located List of All Clinical Sites

The recommended format for the portable document format (PDF) of the comprehensive and
readily located list(s) of all clinical sites that participated in clinical studies for each major (i.e.,
pivotal) study is provided in Appendix 1 of this Guide.

B. Table Listing All Entities To Whom Sponsor Has Contracted Clinical Study-Related Activities

In the table(s) listing entities to whom the sponsor has contracted clinical study-related activities, which are provided in a PDF for each pivotal study, the applicant should identify the location of study-related documents for each study and whether they are sponsor- or Contract Research Organization-generated. For example, these documents may include, but are not limited to, monitoring plans and reports, training records, and data analysis plans (e.g., items that some applicants organize in a Trial Master File). When the location of study-related documents has not been finalized, the applicant should provide contact information (i.e., phone number and

¹ We update technical conformance guides periodically. For the most recent version of this Guide, check the FDA guidance web page at <u>https://www.fda.gov/regulatory-information/search-fda-guidance-documents</u>.

² See FDA guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* (February 2020). We update guidances periodically. For the most recent version of a guidance, check the FDA guidance web page at <u>https://www.fda.gov/regulatory-information/search-fda-guidance-documents.</u>

email address) for the individual(s) who can provide updated location information upon request. This information ensures that when CDER issues an inspection assignment for the application, the inspection is of the most responsible entity for a given regulatory responsibility, and that the

43 inspection assignment is issued for the location where records are present for review.

44

40 41

42

45

C. Protocol, Protocol Amendments, and Annotated Case Report Form

46 47 The protocol and protocol amendments, with associated versions of the case report form, and the 48 final version of the annotated case report form (case report form containing Clinical Data 49 Interchange Standards Consortium and Study Data Tabulation Model (SDTM) annotations) are 50 generally included in Appendix 16³ of the Clinical Study Report or in the datasets folder for each 51 study. When these items are included in an appendix to the Clinical Study Report or the dataset 52 folder for the study, there is no need to resubmit them. If the applicant is submitting a BIMO 53 Reviewer's Guide, the applicant should note that these items are present in an appendix of the 54 Clinical Study Report or the dataset folder and provide hyperlinks to their locations. 55 56 These items are included in the background materials provided to the Office of Regulatory

Affairs for BIMO inspections; it is important to provide all versions of these documents so that
the field investigator performing the inspection can reference the correct versions of protocols
and case report forms in place at the time of the conduct of specific study procedures.

- 60 61
- 62

2 II. SUBJECT-LEVEL DATA LINE LISTINGS BY CLINICAL SITE

63 64

65

A. Organization of the Subject-Level Data Line Listings

Examples of the formatting for the PDF of subject-level data line listings provided for each
major (i.e., pivotal) study used to support safety and efficacy in the application, including studies
with different treatment indications, are provided in Appendix 2 of this Guide. If the sponsor
believes alternative listings or formats are preferable for its submission, proposed alternatives
should be discussed with the Office of Scientific Investigations in advance of the application
submission—for example, before or during pre-NDA or pre-BLA meetings.

For clinical investigator sites involved in multiple studies in support of an application, the
 subject listings should be provided independently for each study within the study-associated
 PDF.

75 76

Subject-level data line listings, by clinical site, should include consented subjects, treatment
assignment, discontinuations, study population, inclusion and exclusion criteria, adverse events,
important protocol deviations, efficacy endpoints, concomitant medications, and safety
monitoring, as further described below.

81 82

1. Consented Subjects

³ See ICH guidance for industry E3 Structure and Content of Clinical Study Reports (July 1996).

84 This by-subject, by-clinical site listing includes all subjects that consented to enroll in the study. 85 Consented subjects that were screen failures should also be included. For subjects that consented 86 but were not randomized to treatment or did not receive investigational product, the specific 87 reason they were not randomized or treated should be included in this listing. 88 89 2. Treatment Assignment 90 91 This by-subject, by-clinical site listing includes the treatment assignment to which the subject 92 was randomized. If a subject mistakenly received treatment different from the subject's assigned 93 treatment for any duration of time, the actual treatment received should also be included. 94 95 3. **Discontinuations** 96 97 This by-subject, by-clinical site listing includes: 98 99 • All subjects that discontinued during run-in period (if applicable) 100 • All subjects that discontinued from study treatment • All subjects that discontinued from the study completely 101 102 103 For each subject, the date of and reason for discontinuation should be provided. 104 105 4. Study Population 106 107 This by-subject, by-clinical site listing identifies the protocol-defined study population in which 108 each subject was analyzed (e.g., intent-to-treat, safety, per protocol). For subjects that did not 109 meet criteria for inclusion in the per-protocol population, the reason they were excluded from the 110 per-protocol population should be provided. 111 112 5. Inclusion and Exclusion Criteria 113 114 This by-subject, by-clinical site listing should display whether each subject met each inclusion and exclusion criterion defined in the protocol. 115 116 117 6. Adverse Events 118 119 This by-subject, by-clinical site listing should include all adverse events (i.e., nonserious adverse 120 events and serious adverse events, including deaths), date of occurrence and time if collected, 121 treatment(s) administered, severity, whether considered serious by the clinical investigator, 122 whether considered serious by the sponsor, action taken, whether the event led to discontinuation 123 of study therapy, and outcome/date of resolution. 124 125 7. Important Protocol Deviations 126

This by-subject, by-clinical site listing should include all protocol deviations. The listing should 127 128 include a description of the deviation and identify whether the sponsor considered the deviation 129 to be an important or non-important protocol deviation.⁴ 130 131 8. Efficacy Endpoints 132 133 This by-subject, by-clinical site listing(s) should contain primary and key secondary efficacy 134 parameters or events. For derived or calculated endpoints, the raw data points used to generate 135 the derived or calculated endpoint should be provided. When efficacy endpoints are collected as 136 clinical events, a by-subject, by-clinical site listing should be provided that includes clinical 137 event date of event, and when adjudicated, the date of adjudication and the outcome of the 138 adjudication process. 139 140 9. **Concomitant Medications** 141 142 This by-subject, by-clinical site listing should contain all concomitant medications as specified by the protocol. The date started, date stopped, dose, route of administration, and reason for 143 144 administration should be included. 145 146 10. Safety Monitoring 147 148 This by-subject, by-clinical site listing(s) should contain results of tests (e.g., laboratory, 149 electrocardiogram) performed for safety monitoring as defined in the protocol. When safety 150 endpoints are collected as clinical events, a by-subject, by-clinical site listing should be provided 151 that includes clinical event, date of event, and when adjudicated, the outcome of the adjudication 152 process. 153 154 **B**. **Site-Specific Listings Format** 155 156 The specified data line listings are anticipated to fit reporting requirements for most applications. 157 If a sponsor believes additional listings are needed to permit FDA to verify key study data during 158 inspections, additional listings should be included. If the size of the PDF file exceeds 500 159 megabytes, it should be split into smaller components.⁵ 160 161 Although listings are currently requested in PDF format, CDER is in the process of developing 162 tools to extract site-specific listings, needed for inspectional purposes, from submitted Clinical 163 Data Interchange Standards Consortium, SDTM, and Analysis Data Model (ADaM) datasets and 164 intends to make those tools available in the future. FDA intends to update these technical 165 specifications to include details for the submission of SDTM and ADaM datasets, including 166 controlled terminology standards. In anticipation of the development of CDER tools for

⁴ See ICH guidance for industry *E3 Structure and Content of Clinical Study Reports — Questions and Answers (R1)* (January 2013).

⁵ See ICH guideline *Specification for Submission Formats for eCTD v1.2* (June 2018) at http://estri.ich.org/ssf/Specification for Submission Formats for eCTD v1 2.pdf.

167 extraction of by-site, by-subject data listings, sponsors should ensure that they are prepared to 168 submit clinical study data using standards specified in the Data Standards Catalog.⁶ 169 170 171 III. SUMMARY-LEVEL CLINICAL SITE DATASET 172 173 A. **Organization of the Site-Level Dataset** 174 175 A single summary-level clinical site dataset that contains data from all major (i.e., pivotal) 176 studies used to support safety and efficacy in the application, including studies with different 177 treatment indications, should be provided. 178 179 For each major (i.e., pivotal) study used to support safety and efficacy, data by clinical site and 180 treatment arm for the safety population (SAFPOP) should be provided. 181 182 For clinical investigator sites involved in multiple studies in support of an application, the site 183 data should be reported independently for each study within the dataset. 184 185 **B**. Variables and Variable Names for Site-Specific Efficacy Results 186 187 For each study and investigator site, it is critical to submit the following variables associated 188 with efficacy and their variable names: 189 Treatment Efficacy Result (TRTEFFR) — The summary statistic for each primary efficacy 190 endpoint, by treatment arm at a site. Values reported in TRTEFFR generally reflect simple 191 summary statistics for the primary efficacy endpoint(s). The method used for deriving the 192 TRTEFFR, including a description of which analysis datasets and associated variables are 193 used to derive the TRTEFFR, should be described in the data define table provided with the 194 clinsite.xpt file. (See discussion below for examples of summary statistics according to 195 different types of efficacy endpoints.) 196 Treatment Efficacy Result Standard Deviation (TRTEFFS) — The standard deviation (STD) • 197 of the summary statistic (TRTEFFR) for each primary endpoint, by treatment arm. The 198 method used to calculate STD should be included in the data define table. 199 • Endpoint (ENDPOINT) — A plain-text label that describes the primary endpoint as 200 described in the data definition file data dictionary included with each application. 201 Treatment Arm (ARM) — A plain-text label for the treatment arm that is used in the Clinical • 202 Study Report. 203 In addition, for studies whose primary endpoint is a time-to-event endpoint, it is critical to 204 include the following data element:

⁶ Available at <u>http://www.fda.gov/forindustry/datastandards/studydatastandards/default.htm</u>.

- Censored Observations (CENSOR) The number of censored observations for the given site and treatment.
- If a study does not contain a time-to-event endpoint, this data element should be recorded as a
 missing value (if not applicable, leave blank in clinsite.xpt).
- 209
- To accommodate the variety of endpoint types that can be used in analyses, it is critical that the following endpoint type definitions be referenced, and summaries be provided when tabulating the site-specific summary statistic by treatment arm (TRTEFFR):
- Discrete Endpoints Endpoints based on efficacy observations that can take on a discrete number of values (e.g., binary, categorical). Summarize discrete endpoints by an event frequency (i.e., number of events), proportion of patients with an event, proportion of patients responding to treatment, or similar method at the site for the given treatment.
- Continuous Endpoints Endpoints based on efficacy observations that can take on an
 infinite number of values. Summarize continuous endpoints by the mean, median, or other
 distributional quantile of the observations at the site for the given treatment.
- Time-to-Event Endpoints Endpoints where the time to occurrence of an event is the primary efficacy measurement. Summarize time-to-event endpoints by two data elements: the number of events that occurred (TRTEFFR) and the number of censored observations (CENSOR).
- Other If the primary efficacy endpoint cannot be summarized in terms of the previous
 guidelines, a single value or multiple values with precisely defined variable interpretations
 should be submitted as part of the dataset.
- In all cases, the endpoint description provided in the ENDPOINT plain-text label should be
 expressed clearly to interpret the value provided in the TRTEFFR variable.
- 229
- When more than one primary efficacy endpoint exists, additional rows should be added to the
 dataset to report additional ENDPOINT, Primary Endpoint Type (ENDPTYPE), TRTEFFR, and
 TRTEFFS values by arm for each site.
- It is anticipated that efficacy data for all subjects included in the SAFPOP variable will be
 included in TRTEFFR and TRTEFFS variables reported. If efficacy data is not available for all
- subjects reported in the SAFPOP variable, then efficacy data for these subjects should be
- reported as specified in the study Data Analysis Plan, and the method used for calculation of efficacy variables should be described in the data define table provided with the clinsite.xpt file.
- 238 239
- The summary-level clinical site dataset should be accompanied by a data definition file. The contents of the define file for a dataset and fictional examples are presented in Appendix 3 and Appendix 4 of this Guide.
- 243
- 244 C. Creating the Data File (Template and Structure)
- 245

A sample summary-level clinical site data submission using the variables identified in Appendix3 of this Guide is provided in Appendix 4.

- 248 249
- 249 250

IV. SUBMITTING BIMO CLINICAL DATA IN THE eCTD FORMAT

251252 Clinical study-level information, subject-level data line listings by clinical site, and the

summary-level clinical site dataset submitted with an application, in Electronic Common

254 Document (eCTD) format, should be placed in eCTD Module 5 (M5) — Clinical Study Reports,

255 using the following conventions:

256

A. Study Tagging File

257

258 Construct a BIMO study tagging file (STF) and place it in eCTD Module 5.3.5.4, "Other Study 259 reports and related information." The study identifier (ID) for this STF is "BIMO." Files 260 described in section III (e.g., Description of Clinical Study-Level Information, Subject-Level 261 Data Line Listings by Clinical Site, and Summary-Level Clinical Site Dataset) of the draft guidance Standardized Format for Electronic Submission of NDA and BLA Content for the 262 Planning of Bioresearch Monitoring (BIMO) Inspections for CDER Submissions (February 263 2018) are linked to this BIMO STF using file tags as indicated below.⁷ Leaf titles for these data 264 265 are named "BIMO [list study ID, followed by brief description of file being submitted]." 266

Requested Item	STF File Tag	Used For	Required File Formats
III.A.1-2	data-listing-dataset	General clinical study- level information	.pdf
III.A.3	Protocol-or-amendment	Protocol and Protocol Amendments, by study	.pdf
III.A.3	annotated-crf	Sample annotated case report form, by study	.pdf
III.B	data-listing-dataset	Data listings, by study (Line listings, by site)	.pdf
III.C	data-listing-dataset	Site-level dataset, across studies	.xpt
III.C	data-listing-data- definition	Define file	.xml
Optional	data-listing-dataset	BIMO Reviewer's Guide	.pdf

267 Table 1: STF File Tags

268

269 270

270

B. eCTD Folder Structure for Clinical Study-Level Information and Subject-Level Line Listings by Clinical Site

⁷ When final, this guidance will represent the FDA's current thinking on this topic.

Clinical study-level information and subject-level line listings by clinical site are submitted for each major (i.e., pivotal) study used to support safety and efficacy in the application.

Within the eCTD folder structure, place clinical study-level information and subject-level line listings by clinical site in the M5 folder as follows:

277

274

Figure 2: Place Clinical Study-Level Information and Subject-Level Line Listings by Clinical Site in the M5 Folder

280

🗸 📙 Module 5	^	Name
✓ datasets		🔁 Study 001 Sample Annotated CRF (III.A.3).pdf
🗸 🔤 bimo		🔁 Study 001 Protocol and Amendments (III.A.3).pdf
Site-level		🔁 Study 001 Listing All Clinical Sites (III.A.1).pdf
Study 001		🔁 Study 001 Data Line Listings by Clinical Site (III.B).pdf
Study 002		🔁 Study 001 Contracted Clinical Study-Related Activities (IIIA.2).pdf

281 282

283

284

C. eCTD Folder Structure for Summary-Level Clinical Site Dataset


For the site-level dataset, use the filename "clinsite.xpt." A single file containing data from all major (i.e., pivotal) studies used to support safety and efficacy in the application should be provided.

287 F 288

Within the eCTD folder structure, place the site-level dataset define file and BIMO Reviewer'sGuide, if it is being submitted, in the M5 folder as follows:

291

Figure 2: Place the Site-Level Dataset Define File and BIMO Reviewer's Guide in the M5 Folder



The Clinical Study-Level Information and Subject-Level Data Line Listings by Clinical Site should be submitted in PDF (*.pdf). When submitting a BIMO Reviewer's Guide, it should also be submitted in PDF (*.pdf). The summary-level clinical site data should be submitted in SAS

transport file format (*.xpt). The define file for the summary-level clinical site data should be
 submitted in Extensible Markup Language (define.xml) format. For more information, see the
 *Study Data Technical Conformance Guide.*⁸

305 E. Leaf Titles

306

Leaf titles for study-level information and study-level, subject-level data line listings by clinical
site are named "BIMO [list study ID, followed by brief description of file being submitted]." For
the leaf representing the clinite.xpt dataset, please clearly identify it with the leaf title "BIMO
summary-level clinical site data."

311 312

313

316

F. Submission

See the technical specifications in *Transmitting Electronic Submissions Using eCTD Specifications* for details on electronic transmission or physical media submissions.⁹

- 317 The following are helpful references for eCTD submission:
- ICH eCTD STF Specification V 2.6.1, *The eCTD Backbone File Specification for Study Tagging Files* (June 2008) (available at <u>http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequ</u> irements/ElectronicSubmissions/UCM163560.pdf).
- FDA guidance for industry *Providing Regulatory Submissions in Electronic Format* –
 Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (February 2020) (available at <u>https://www.fda.gov/regulatory-</u>
 information/search-fda-guidance-documents).
- FDA eCTD web page
 (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/E
 lectronicSubmissions/ucm153574.htm.).
- For general help with eCTD submissions, submit your questions to the following email address: <u>ESUB@fda.hhs.gov</u>.
- 331
- 227
- 332

⁹ Available at

⁸ Available at <u>https://www.fda.gov/industry/fda-resources-data-standards/study-data-standards-resources.</u>

<u>http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/FormsSubmissionRequirements/ElectronicSubmissions/UCM163567.pdf</u>.

333 APPENDIX 1: CLINICAL STUDY-LEVEL INFORMATION

334

335 *Format for comprehensive and readily located list of all clinical sites that participated in each*


336 *clinical study. A separate table should be provided for each clinical study.*

Protocol Number: Protocol Title Site Address at Time of **Site Contact** Site Investigator Identifier Name **Clinical Study Information at Time** (Prior Clinical (Updated Site Address of Clinical Study **Investigator(s)**) when exists and available) (Updated Contact Information when exists and available) LASTNAME, **FACILITY NAME** PHONE SITEID FRSTNAME, STREET FAX MINITIAL **CITY, STATE, POSTAL EMAIL COUNTRY** 0001* Doe, John M. Doe University Department of Phone: 1-555-555-5555 Medicine Fax: 1-555-555-5555 1 Main St., Suite 100 Email: Silver Spring, MD 20850 john.doe@mail.com USA 0002 Doe University Department of Doe, Jean Phone: 1-555-555-5555 (Smith, John) Fax: 1-555-555-5555 Medicine 1 Main St., Suite 100 Email: Silver Spring, MD 20850 john.smith@mail.com USA (Phone: 1-555-555-5554 Email: jean.doe@mail.com) 003 Dietric-Fischer, Hartmannstrasse 7 Phone:49-555-555-5555 Inge 5300 Bonn 1 Fax: 49-555-555-5555 Germany Email: Dietric.Fischer@web.de * Site terminated, or clinical investigator changed, at request of sponsor before study completion.

337 Table A: Format for Clinical Site Lists


340 APPENDIX 2: FORMATTING SUBJECT-LEVEL DATA LINE LISTINGS BY 341 CLINICAL SITE

- 342
- 343 By Site, by Listing Option A:
- 344
- 345 Figure A: By Site, by Listing Option A



346 347

348 By Site, by Subject Profile Option B:




350 Figure B: By Site, by Subject Profile Option B

353 Example of By Site, by Listing Option A:

354

355 Figure C: Example of By Site, by Listing Option A



+

+

Site #0002

Site #0003

+

Subject Number #0001-064

Subject Number #0001-101

APPENDIX 3: CLINICAL SITE DATA ELEMENTS SUMMARY LISTING

Variable Index		Variable Label	Туре	Controlled Terms or Format	Notes or Description	Sample Value
1	STUDYID	Study Identifier	Char	String	Study or trial identification number.	ABC-123
2	TITLE	Study Title	Char	String	Title of the study as listed in the clinical study report (limit 200 characters). If the title exceeds 200 characters, provide shortened title and define (e.g., use the abbreviated title from clinicaltrial.gov).	Double blind, randomized, placebo- controlled clinical study on the influence of drug X on indication Y
3	SPONCNT	Sponsor Count	Num	Integer	Total count of sponsors throughout the study. If there was a change in the sponsor while the study was ongoing, with sponsors as defined in § 312.3 (21 CFR 312.3), enter an integer indicating the total count of sponsors. If there was no change in the sponsor while the study was ongoing, enter "1."	1
4	SPONSOR	Sponsor Name	Char	String	Full name of the sponsor organization conducting the study at the time of study completion, as sponsor is defined in § 312.3. If the sponsor name exceeds 200 characters, provide short-form sponsor name and define.	DrugCo, Inc.
5	IND	IND Number	Num	6 digit identifier	IND number. If study not performed under IND, leave blank.	010010
6	UNDERIND	Under IND	Char	String	Value should equal "Y" if study at the site was conducted under an IND (i.e., a Form FDA 1572 was signed by the investigator) and "N" if study was not conducted under an IND at the site (i.e., a Form FDA 1572 was not signed by the investigator).	Y
7	NDA	NDA Number	Num	6 digit identifier	FDA NDA number, if available/applicable. If not applicable, leave blank.	021212
8	BLA	BLA Number	Num	6 digit identifier	FDA identification number for BLA, if available/applicable. If not applicable, leave blank.	123456
9	SUPPNUM	Supplement Number	Num	Integer	Serial number for supplemental application, if applicable. If no information is available, leave blank.	4
10	SITEID	Study Site Identifier	Char	String	Investigator site identifier assigned by the sponsor.	50
11	ARM	Description of Planned Treatment Arm	Char	String	Plain-text label for the name given to an arm or treatment group as referenced in the clinical study report (limit 200 characters). When no arm or treatment group is available due to only screen failure subjects at site, use label "Screen Failure."	Active name and dose (e.g., "Active 25mg"), Comparator product name (e.g., "Drug x"), Placebo, Screen Failure
12	COHORT	Description of Planned Cohort	Char	String	For cohort studies, the plain-text label given to a cohort as referenced in the clinical study report (limit 200 characters). When not a cohort study, leave blank.	A

Table B: Clinical Site Data Elements Summary Listing

Variable Index					Notes or Description	Sample Value
13	SAFPOP	Number of Subjects in Safety Population	Num	Integer	Total number of subjects in safety population at a given site by treatment arm. When a subject has transferred from one site to another, the applicant should handle reporting of such subjects consistently across sites and include in the define file the reporting convention used. The applicant may opt to further explain the reasons subjects transferred between sites in the BIMO Reviewer's Guide, if a guide will be provided.	20
14	SCREEN	Number of Subjects Screened	Num	Integer	Total number of subjects screened (and consented) at a given site (overall number per site as subjects have not yet been assigned to treatment arm). When a subject has transferred from one site to another, the applicant should handle reporting of such subjects consistently across sites and include the reporting convention used in the define file or the BIMO Reviewer's Guide (if provided). The applicant may opt to further explain the reasons subjects transferred between sites in the BIMO Reviewer's Guide, if provided.	100
15	DISCSTUD	Number Subjects Discont. Study	Num	Integer	Number of subjects in the safety population who discontinued from the study by treatment arm at a given site.	5
16	DISCTRT	Number Subjects Discont. Study Treatment	Num	Integer	Number of subjects in the safety population who discontinued from the study treatment by treatment arm at a given site.	10
17	ENDPOINT	Primary Endpoint	Char	String	Plain-text label used to describe the primary endpoint as described in the define file included with each application (limit 200 characters).	Average increase in blood pressure
18	ENDPTYPE	Primary Endpoint Type	Char	String	Variable type of the primary endpoint (i.e., "continuous," "discrete," "time to event," or "other").	Continuous
19	TRTEFFR	Treatment Efficacy Result	Num	Floating Point	Summary statistic for each primary efficacy endpoint by treatment arm at a given site for subjects in SAFPOP.	1.00
20	TRTEFFS	Treatment Efficacy Result STD	Num	Floating Point	Standard deviation (STD) of the efficacy result (TRTEFFR) for each primary efficacy endpoint by treatment arm at a given site for subjects in SAFPOP. If N=1, set to "0."	0.065
21	CENSOR	Number of Censored Observations	Num	Integer	Total number of censored observations at a given site by treatment arm for primary endpoint (e.g., applicable to time-to-event). If not applicable, leave blank.	5
22	NSAE	Number of Non-Serious Adverse Events	Num	Integer	Total number of nonserious adverse events at a given site by treatment arm for subjects in the SAFPOP. This value should include multiple events per subject and all event types (i.e., not limited to only those that are deemed related to study drug or that are treatment emergent events). When events with the same preferred term have occurred on different dates for a subject, each event should be counted separately in event count.	10

Variable Index	Variable Name	Variable Label	Туре	Controlled Terms or Format	Notes or Description	Sample Value		
23	SAE Number of Serious Adverse Events Num Integer				Total number of serious adverse events, excluding deaths, at a given site by treatment arm for subjects in the SAFPOP. This value should include multiple events per subject. When events with the same preferred term have occurred on different dates for a subject, each event should be counted separately in event count.	5		
24	DEATH	Number of Deaths	Num	Integer	Total number of deaths at a given site by treatment arm for subjects in the SAFPOP.	1		
25	IMPDEV	Number of Important Protocol Deviations	Num	Integer	Total number of important protocol deviations at a given site by treatment arm for subjects in the SAFPOP. A protocol deviation is any change, divergence, or departure from the study design or procedures defined in the protocol or associated investigational plans that is not implemented or intended as a systematic change. This value should include multiple deviations per subject and all major deviation types. Important deviations are those deviations that might significantly affect the completeness, accuracy, and/or reliability of the study data or that might significantly affect a subject's rights, safety, or well-being.	2		
26	NOIMPDEV	Number of Non-Important Protocol Deviations	Num	Integer	Total number of protocol deviations, excluding important protocol deviations, at a given site by treatment arm for subjects in the SAFPOP. A protocol deviation is any change, divergence, or departure from the study design or procedures defined in the protocol or associated investigational plans that is not implemented or intended as a systematic change.	98		
27	FINLDISC	Financial Disclosure Amount	Char	String	Total financial disclosure amount (US\$) by site calculated as the sum of disclosures for the clinical investigator and all sub-investigators, to include all required parities under the applicable regulations (21 CFR 54, 312, 314, 320, 330, 601, 807, 812, 814, and 860). Enter ">=\$25,000," "< \$25,000," "unknown" if a proper value is applicable but is not known (i.e., unable to obtain information from investigator at site), or "masked" if information on this item is available but it has not been provided by the sender due to security, privacy, or other reasons.	>= \$25,000		
28	LASTNAME	Investigator Last Name	Char	String	Last name of the clinical investigator as it appears on the Form FDA 1572 or the signed investigator agreement. At sites where the clinical investigator has changed during the course of the study, the most recent clinical investigator should be listed.	Doe		
29	FRSTNAME	Investigator First Name	Char	String	First name of the clinical investigator as it appears on the Form FDA 1572 or the signed investigator agreement.	John		
30	MINITIAL	Investigator Middle Initial	Char	String	Middle initial of the clinical investigator, if any, as it appears on the Form FDA 1572 or the signed investigator agreement.	М		
31	PHONE	Investigator Phone Number	Char	String	Phone number of the clinical investigator. Include country code for non-U.S. numbers.	44-555-555-5555		

Variable Index	Variable Name	Variable Label	Туре	Controlled Terms or Format	Notes or Description	Sample Value
32	FAX	Investigator Fax Number	Char	String	Fax number of the clinical investigator. Include country code for non-U.S. numbers. If not available, leave blank.	44-555-555-5555
33	EMAIL	Investigator Email Address	Char	String	Email address of the clinical investigator.	John.doe@mail.com
34	COUNTRY	Country	Char	ISO 3166-1-alpha-3	Three-letter International Organization for Standardization (ISO) 3166 country code for the country in which the site is located.	USA
36	STATE	State	Char	String	Unabbreviated state or province in which the site is located. If not applicable, enter "NA."	Maryland
37	CITY	City	Char	String	Unabbreviated city, county, or village in which the site is located.	Silver Spring
38	POSTAL	Postal Code	Char	String	Postal code in which the site is located. If not applicable, enter "NA."	20850
39	STREET	Street Address	Char	String	Street address and office number at which the site is located (limit 200 characters).	2005 John Fitzgerald Kennedy Boulevard Northwest, International Technology Center, Department of Medicine and Pharmacokinetics, National Institute of Clinical Research Twin Towers Building,
40	STREET1	Street Address Continued	Char	String	Street address and office number at which the site is located. Use this field when the STREET variable does not permit sufficient space to fully describe street address and office number at which the site is located.	The Executive Wing, Suite # 209

APPENDIX 4: EXAMPLES

The following is a fictional example of a dataset for a placebo-controlled trial. Four international sites enrolled a total of 205 subjects who were randomized in a 1:1 ratio to active or placebo. In the first example there is a single primary endpoint (percent of responders). In the second example there are co-primary endpoints (percent of responders and change from baseline). Note that since there were two treatment arms, in the first example, each site contains two rows and there are a total of eight rows for the entire dataset. In the second example, each site contains a total of 4 rows, and there are a total of 16 rows for the entire dataset.

Table C: Example for Clinical Site Data Elements Summary Listing with One Endpoint

STUDYID	TITLE	SPONCNT	SPONSOR	IND	UNDER- IND	NDA	BLA	SUPP- NUM	SITEID	ARM	COHORT	SAFPOP	SCREEN	DISCSTUD	DISCTRT
ABC-123	Double blind	1	DrugCo, Inc.	000001	Y	200001	•	•	001	Active	-	26	61	3	2

ABC-123	Double blind	1	DrugCo,	Inc.	000001	Y		200001	•		001	Placebo	-	25	61	4	1
ABC-123	Double blind	1	DrugCo,	Inc.	000001	Y		200001	·	•	002	Active	-	23	54	2	1
ABC-123	Double blind	1	DrugCo,	Inc.	000001	Y		200001	·	•	002	Placebo	-	25	54	4	3
ABC-123	Double blind	1	DrugCo,	Inc.	000001	Y		200001	•	•	003	Active	-	27	62	3	0
ABC-123	Double blind	1	DrugCo,	Inc.	000001	Y		200001	•	•	003	Placebo	-	26	62	5	3
ABC-123	Double blind	1	DrugCo,	Inc.	000001	Y		200001	•	•	004	Active	-	26	60	2	2
ABC-123	Double blind	1	DrugCo,	Inc.	000001	Y		200001	•	•	004	Placebo	-	27	60	1	0
ENDPOIN		IDPTYPE	TRTEFFR	TRTE		ENSOR	NSA	SAE	DEATH	IN	MPDEV	NOIM			NLDISC	LASTNAME	FRSTNAME
Percent		Binary	0.48	0.09			0	2	0		1	-	FDLV 1		\$25,000	Doe	John
Responder Percent	rs					•							3		. ,		
Responder Percent	rs	Binary	0.14	0.06		•	2	2	0		1	ę	9		\$25,000	Doe	John
Responder Percent	rs	Binary	0.48	0.10			3	2	1		0	1			\$25,000	Washington	George
Responder	rs	Binary	0.14	0.06	594		0	2	0		3			>=	\$25,000	Washington	George
Percent Responder	rs	Binary	0.54	0.09	959	•	2	2	0		1	2		>=	\$25,000	Jefferson	Thomas
Percent Responder		Binary	0.19	0.07	769	•	3	6	0		0	7		>=	\$25,000	Jefferson	Thomas
Percent Responder		Binary	0.46	0.09	977		4	1	0		0	8	3	ur	nknown	Lincoln	Abraham
Percent Responder		Binary	0.12	0.06	625	•	1	2	0		1	1	3	ur	nknown	Lincoln	Abraham
MINITIAL	P	HONE	FAX		E	MAIL		COUNTR	Y	STAT	E	CITY	-	POSTAL	STI	REET	STREET1
М	555-	123-4567	555-123-4	560	John@	mail.com		RUS		Mosco	w	Moscow		103009	Kremlir	n Road 1	
М	555-	123-4567	555-123-4	560	John@	mail.com		RUS		Mosco	wc	Moscow		103009	Kremlir	n Road 1	
	020-3	456-7891	020-3456-7	7890	george	@mail.com	n	GBR		Westmir	nster	London		SW1A 2	10 Dov	wning St	
	020-3	8456-7891	020-3456-7	7890	george	@mail.com	n	GBR		Westmir	nster	London		SW1A 2	10 Dov	wning St	
	01-89	-12-34-56	01-89-12-3	4-51	tom@	mail.com		FRA		N/A		Paris		75002	1, Ru	e Road	
	01-89	-12-34-56	01-89-12-3	4-51	tom@	mail.com		FRA		N/A	۱	Paris		75002	· · · · ·	e Road	
	555-	987-6543	555-987-6	540	abe@	mail.com		USA		Maryla	and	Rockville		20852	10903 New Hampshire Avenue, Office of Medic Products and Tobacco, Center for Drug Evaluatio and Research		Building 4, Room 1375
	555-	987-6543	555-987-6	540	abe@	mail.com		USA		Maryla	and	Rockville		20852	10903 New Hampshire Avenue, Office of Medical Products and Tobacco, Center for Drug Evaluation and Research		Building 4, Room 1375

	- P-0 -0- 0							5								
TITLE	SPONCNT	SPONSOR	R IND	U	NDER- IND	ND	DA E	BLA		SITEID	ARM	COHORT	SAFPOP	SCREEN	DISCSTUD	DISCTRT
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	001	Active	A	26	61	3	2
Double	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	001	Active	В	26	61	3	2
Double	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	001	Placebo	A	25	61	4	1
Double	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	001	Placebo	В	25	61	4	1
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	002	Active	A	23	54	2	1
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	·	•	002	Active	В	23	54	2	1
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	·	•	002	Placebo	A	25	54	4	3
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	·	•	002	Placebo	В	25	54	4	3
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	003	Active	A	27	62	3	0
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	003	Active	В	27	62	3	0
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	003	Placebo	A	26	62	5	3
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	003	Placebo	В	26	62	5	3
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	004	Active	A	26	60	2	2
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	004	Active	В	26	60	2	2
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	004	Placebo	A	27	60	1	0
Double blind	1	DrugCo, Inc	c. 00000)1	Y	2000	001	•	•	004	Placebo	В	27	60	1	0
NT	ENDPTYPE	TRTEFFR	TRTEFFS	CENS		ISAE	SAE	DEA	лн ш	MPDEV	NOIMPDE	V FINL	DISC	LASTN	AME	FRSTNAME
t	Binary	0.48	0.0980	•		0	2	C)	1	5	< \$2	5,000	Doe	•	John
om	Continuous	0.74	0.0861	•		0	2	C)	1	8	< \$2	5,000	Doe	e	John
t	Binary	0.14	0.0694			2	2	0)	1	5	< \$2	5,000	Doe	e	John
om	Continuous	0.14	0.0699	·		2	2	C)	1	8	< \$2	5,000	Doe	e	John
t	Binary	0.48	0.1042	•		3	2	1		0	11	>= \$2	5,0000	Washin	gton	George
om	Continuous	0.67	0.0983	•		3	2	1		0	13	>= \$2	5,0000	Washin	gton	George
t ers	Binary	0.14	0.0694	•		0	2	0)	3	11	>= \$2	5,0000	Washin	gton	George
	Double blind Double blind Double blind Double blind Double blind Double blind Double blind Double blind Double blind Double blind Double blind Double blind Double blind Double blind Double blind Double blind Double blind T T rs m rs m	Double blind1Double <br< td=""><td>Double blind1DrugCo, Inc.Double blind1DrugCo, Inc.TTENDPTYPETRTEFFRrs Binary0.48om continuous0.14om om Continuous0.67Binary0.14</td><td>Double blind 1 DrugCo, Inc. 00000 Double blind 1<</td><td>TILE SPONCNT SPONSOR IND Double 1 DrugCo, Inc. 000001 Ind Doubl</td><td>Double blind 1 DrugCo, Inc. 000001 Y Double blind 1 DrugCo, Inc. 00</td><td>TITLE SPONCNT SPONSOR IND IND NL Double blind 1 DrugCo, Inc. 000001 Y 2000 Double blind 1</td><td>ITTLE SPONCNI SPONSOR IND IND NDA I Double blind 1 DrugCo, Inc. 000001 Y 200001 Double Double blind 1 DrugCo, Inc. 000001 Y</td><td>TITLE SPONCNT SPONSOR IND UNDER- IND NDA BLA Double blind 1 DrugCo, Inc. 000001 Y 200001 Double blind 1 DrugCo, Inc. 000001 Y 200001</td><td>TITLE SPONCNT SPONSOR IND UNDER- IND NDA BLA SUPP- NUM Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · <</td><td>TITLE SPONCNT SPONSOR IND UNDER- IND NDA BLA SUPP- NUM SITEID Double blind 1 DrugCo, Inc. 000001 Y 200001 · · 001 Double blind 1 DrugCo, Inc. 000001 Y 200001 · · 001 Double blind 1 DrugCo, Inc. 000001 Y 200001 · · 001 Double blind 1 DrugCo, Inc. 000001 Y 200001 · · 002 Double blind 1 DrugCo, Inc. 000001 Y 200001 · 002 Double blind 1 DrugCo, Inc. 000001 Y 200001 · 002 Double blind 1 DrugCo, Inc. 000001 Y 200001 · 003 Double blind 1 DrugCo, Inc. 000001 Y 200001 · · 003 Double blind <</td><td>TITLE SPONCNT SPONSOR IND UNDER- IND NDA BLA SUPP- NUM SITEID ARM Double bind 1 DrugCo, Inc. 000001 Y 200001 001 Active Double bind 1 DrugCo, Inc. 000001 Y 200001 001 Active Double bind 1 DrugCo, Inc. 000001 Y 200001 001 Placebo Double bind 1 DrugCo, Inc. 000001 Y 200001 002 Active Double bind 1 DrugCo, Inc. 000001 Y 200001 002 Active Double bind 1 DrugCo, Inc. 000001 Y 200001 002 Placebo Double bind 1 DrugCo, Inc. 000001 Y 200001 003 Active Double bind 1 DrugCo, Inc. 000001 Y 20001 003 Placebo Double bind 1 DrugCo, Inc.</td><td>TITLE SPONCNT SPONSOR IND UNDER- IND NDA BLA SUPP- NUM SITEID ARM COHORT Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 001 Active A Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 001 Active A Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 001 Placebo A Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 002 Active A Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 002 Placebo A Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 003 Active B Double Indid. 1 DrugCo, Inc. 000001 Y 200001</td><td>TITLE SPONCNT SPONSOR IND UNDER LABOR NDA BLA SUPP- NUM SITE ID ARM COHORT SAFPOP Double 1 DrugCo, Inc. 000001 Y 200001 011 Active A 26 Double 1 DrugCo, Inc. 000001 Y 200001 011 Active A 26 Double 1 DrugCo, Inc. 000001 Y 200001 011 Placebo A 25 Double 1 DrugCo, Inc. 000001 Y 200001 002 Active A 23 Double 1 DrugCo, Inc. 000001 Y 200001 002 Active B 23 Double 1 DrugCo, Inc. 000001 Y 200001 002 Placebo B 25 Double 1 DrugCo, Inc. 00001 Y 20001 003 Active A 26 Double</td><td>TITLE SPONCNT SPONSOR IND IND INDA BLA SUPP- NUM SITEID ARM COHORT SAFPOP SCREEN Double Double 1 DrugCo, Inc. 000001 Y 200001 '' 001 Active A 26 61 Double 1 DrugCo, Inc. 000001 Y 200001 '' 001 Active B 26 61 Double 1 DrugCo, Inc. 000001 Y 200001 '' 001 Placebo A 25 61 Double 1 DrugCo, Inc. 000001 Y 200001 '' 002 Active A 23 54 Double 1 DrugCo, Inc. 000001 Y 200001 '' 002 Placebo A 25 54 Double 1 DrugCo, Inc. 00001 Y 20001 '' 003 Active A 26 62</td><td>$\begin{array}{c c c c c c c c c c c c c c c c c c c$</td></br<>	Double blind1DrugCo, Inc.Double blind1DrugCo, Inc.TTENDPTYPETRTEFFRrs Binary0.48om continuous0.14om om Continuous0.67Binary0.14	Double blind 1 DrugCo, Inc. 00000 Double blind 1<	TILE SPONCNT SPONSOR IND Double 1 DrugCo, Inc. 000001 Ind Doubl	Double blind 1 DrugCo, Inc. 000001 Y Double blind 1 DrugCo, Inc. 00	TITLE SPONCNT SPONSOR IND IND NL Double blind 1 DrugCo, Inc. 000001 Y 2000 Double blind 1	ITTLE SPONCNI SPONSOR IND IND NDA I Double blind 1 DrugCo, Inc. 000001 Y 200001 Double Double blind 1 DrugCo, Inc. 000001 Y	TITLE SPONCNT SPONSOR IND UNDER- IND NDA BLA Double blind 1 DrugCo, Inc. 000001 Y 200001 Double blind 1 DrugCo, Inc. 000001 Y 200001	TITLE SPONCNT SPONSOR IND UNDER- IND NDA BLA SUPP- NUM Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · · Double blind 1 DrugCo, Inc. 000001 Y 200001 · <	TITLE SPONCNT SPONSOR IND UNDER- IND NDA BLA SUPP- NUM SITEID Double blind 1 DrugCo, Inc. 000001 Y 200001 · · 001 Double blind 1 DrugCo, Inc. 000001 Y 200001 · · 001 Double blind 1 DrugCo, Inc. 000001 Y 200001 · · 001 Double blind 1 DrugCo, Inc. 000001 Y 200001 · · 002 Double blind 1 DrugCo, Inc. 000001 Y 200001 · 002 Double blind 1 DrugCo, Inc. 000001 Y 200001 · 002 Double blind 1 DrugCo, Inc. 000001 Y 200001 · 003 Double blind 1 DrugCo, Inc. 000001 Y 200001 · · 003 Double blind <	TITLE SPONCNT SPONSOR IND UNDER- IND NDA BLA SUPP- NUM SITEID ARM Double bind 1 DrugCo, Inc. 000001 Y 200001 001 Active Double bind 1 DrugCo, Inc. 000001 Y 200001 001 Active Double bind 1 DrugCo, Inc. 000001 Y 200001 001 Placebo Double bind 1 DrugCo, Inc. 000001 Y 200001 002 Active Double bind 1 DrugCo, Inc. 000001 Y 200001 002 Active Double bind 1 DrugCo, Inc. 000001 Y 200001 002 Placebo Double bind 1 DrugCo, Inc. 000001 Y 200001 003 Active Double bind 1 DrugCo, Inc. 000001 Y 20001 003 Placebo Double bind 1 DrugCo, Inc.	TITLE SPONCNT SPONSOR IND UNDER- IND NDA BLA SUPP- NUM SITEID ARM COHORT Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 001 Active A Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 001 Active A Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 001 Placebo A Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 002 Active A Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 002 Placebo A Double Indid. 1 DrugCo, Inc. 000001 Y 200001 · · 003 Active B Double Indid. 1 DrugCo, Inc. 000001 Y 200001	TITLE SPONCNT SPONSOR IND UNDER LABOR NDA BLA SUPP- NUM SITE ID ARM COHORT SAFPOP Double 1 DrugCo, Inc. 000001 Y 200001 011 Active A 26 Double 1 DrugCo, Inc. 000001 Y 200001 011 Active A 26 Double 1 DrugCo, Inc. 000001 Y 200001 011 Placebo A 25 Double 1 DrugCo, Inc. 000001 Y 200001 002 Active A 23 Double 1 DrugCo, Inc. 000001 Y 200001 002 Active B 23 Double 1 DrugCo, Inc. 000001 Y 200001 002 Placebo B 25 Double 1 DrugCo, Inc. 00001 Y 20001 003 Active A 26 Double	TITLE SPONCNT SPONSOR IND IND INDA BLA SUPP- NUM SITEID ARM COHORT SAFPOP SCREEN Double Double 1 DrugCo, Inc. 000001 Y 200001 '' 001 Active A 26 61 Double 1 DrugCo, Inc. 000001 Y 200001 '' 001 Active B 26 61 Double 1 DrugCo, Inc. 000001 Y 200001 '' 001 Placebo A 25 61 Double 1 DrugCo, Inc. 000001 Y 200001 '' 002 Active A 23 54 Double 1 DrugCo, Inc. 000001 Y 200001 '' 002 Placebo A 25 54 Double 1 DrugCo, Inc. 00001 Y 20001 '' 003 Active A 26 62	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $

 Table D: Example for Clinical Site Data Elements Summary Listing with Multiple Primary Endpoints

ENDPOI	NT ENDPT	YPE TRTEFF	R TRTEFFS	CENSOR	NSAE	SAE	DEATH	IMPDEV	NOIMPDEV	FINLDISC	LASTNAME	FRSTNAM
Change fr Baselin	ie Continu	ous 0.14	0.0700	·	0	2	0	3	13	>= \$25,0000	Washington	George
Percer Respond	Binai	y 0.54	0.0959	•	2	2	0	1	9	>= \$25,0000	Jefferson	Thomas
Change fr Baselin	rom Continu	ous 0.65	0.0931	•	2	2	0	1	5	>= \$25,0000 Jefferson		Thomas
Percer	nt Binai	y 0.19	0.0769	•	3	6	0	0	9	>= \$25,0000	Jefferson	Thomas
Respond Change fr	rom	-					-		5			
Baselin	ie Continu	ous 0.19	0.0769		3	6	0	0		>= \$25,0000	Jefferson	Thomas
Percer Respond	Binai	y 0.46	0.0977		4	1	0	0	0	unknown	Lincoln	Abraham
Change fi Baselin		ous 0.71	0.0891	•	4	1	0	0	3	unknown	Lincoln	Abraham
Percer Respond	nt Binai	y 0.12	0.0625	•	1	2	0	0	0	unknown	Lincoln	Abraham
Change fr Baselin		ous 0.15	0.0694	•	1	2	0	1	3	unknown	Lincoln	Abraham
	·	·	·									·
MINITIAL	PHONE	FAX	EN	1AIL	COUNTR	Y	STATE	CITY	POSTAL	STR	EET	STREET1
М	555-123-4567	555-123-45	60 John@	mail.com	RUS		Moscow	Moscow	103009	Kremlin	Kremlin Road 1	
М	555-123-4567	555-123-45	60 John@	mail.com	RUS		Moscow	Moscow	103009	Kremlin	Road 1	
М	555-123-4567	555-123-45	60 John@	mail.com	RUS		Moscow	Moscow	103009	Kremlin	Road 1	
М	555-123-4567	555-123-45	60 John@	mail.com	RUS		Moscow	Moscow	103009	Kremlin	Road 1	
•	020-3456-7891	020-3456-7	890 george@	mail.com	GBR	W	estminster	London	SW1A 2	10 Downing S	St Suite 2058	
•	020-3456-7891	020-3456-7	890 george@	mail.com	GBR	W	estminster	London	SW1A 2	10 Downing S	St Suite 2058	
•	020-3456-7891	020-3456-7	890 george@	@mail.com	GBR	W	estminster	London	SW1A 2	10 Downing S	St Suite 2058	
•	020-3456-7891	020-3456-7	890 george@	mail.com	GBR	W	estminster	London	SW1A 2	10 Downing S	St Suite 2058	
•	01-89-12-34-56	01-89-12-34	-51 tom@r	nail.com	FRA		N/A	Paris	75002	1, Rue	Road	
•	01-89-12-34-56	01-89-12-34	-51 tom@r	nail.com	FRA		N/A	Paris	75002	1, Rue	Road	
•	01-89-12-34-56	01-89-12-34	-51 tom@r	nail.com	FRA		N/A	Paris	75002	1, Rue	Road	
•	01-89-12-34-56	01-89-12-34	-51 tom@r	nail.com	FRA		N/A	Paris	75002	1, Rue		
	555-987-6543	555-987-65	40 abe@r	nail.com	USA	٩	Maryland	Rockville	20852	Boulevard Northw Technology Cente Medicine and Ph National Institute of	2005 John Fitzgerald Kennedy Boulevard Northwest, International Technology Center, Department of Medicine and Pharmacokinetics, National Institute of Clinical Research Twin Towers Building,	
•	555-987-6543	555-987-65	40 abe@r	nail.com	USA	ז	Maryland	Rockville	20852	2005 John Fitzg Boulevard Northw Technology Cente Medicine and Ph National Institute of Twin Tower	gerald Kennedy vest, International er, Department of narmacokinetics, f Clinical Research	The Executive Wing, Suite # 209

MINITIAL	PHONE	FAX	EMAIL	COUNTRY	STATE	CITY	POSTAL	STREET	STREET1
·	555-987-6543	555-987-6540	abe@mail.com	USA	Maryland	Rockville	20852	2005 John Fitzgerald Kennedy Boulevard Northwest, International Technology Center, Department of Medicine and Pharmacokinetics, National Institute of Clinical Research Twin Towers Building,	The Executive Wing, Suite # 209
	555-987-6543	555-987-6540	abe@mail.com	USA	Maryland	Rockville	20852	2005 John Fitzgerald Kennedy Boulevard Northwest, International Technology Center, Department of Medicine and Pharmacokinetics, National Institute of Clinical Research Twin Towers Building,	The Executive Wing, Suite # 209